CLK / DYRK1A inhibitor Lorecivivint treatment of knee osteoarthritis: Phase IIa clinical lying results!

Samumed Pharmaceuticals recently announced the results of a Phase IIa clinical trial of the research CLK/DYRK1A inhibitor Lorecivivint for the treatment of knee osteoarthritis (OA), demonstrating the potential of lorecivivint to improve diseaseOA's evidence-based treatments include non-drug therapy, medication, and surgery designed to relieve pain, improve joint function, and change risk factors for osteoarthritis progressionDespite the researchers' efforts, the treatments aimed at changing the course of the disease have been less effectiveDr Yusuf Yazici, Chief Medical Officer, Samumed, said: "Narrowing joint clearance/cartilage loss in OA patients is a biomarker of progression in OA diseasePhase IIa data show that lorecivivint has the ability to slow the narrowing of joint gaps while continuing to improve patient pain for more than a year."this is a multicenter, randomized, double-blind, placebo-controlled Phase IIa study (NCT02536833) that assessed the safety, tolerance and effectiveness of single injections of lorecivivint in patients with moderate to severe symptomatic OA over a 52-week period455 subjects were randomly assigned to receive 0.03, 0.07, 0.23 mg lorecivivint or placebo